 Centessa Pharmaceuticals plc NASDAQ: CNTA announced proof-of-mechanism data from the first three subjects in Phase 1 Part B study of ZF874 in Alpha-1 Antitrypsin Deficiency AATD. AATD is an autosomal recessive disorder frequently caused by missense mutations in the A1AT gene. 